Zentalis at Stifel 2026 Healthcare Conference: dual path for azenosertib
At a glance
- $ZNTL today−7.50%last $1.48
- Vs industry peers−6.39 pts6-peer median −1.11% · far behind
- Since Nov 11−20.5%from the first trade after the story
- 52-week range15.6% above low$1.28 – $6.95
- Cash runway~2 mo$24.0M cash ÷ $11.5M/mo burn · 10-Q
- Coverage6 this week20 in 30 days · about its usual pace
Nothing reported about zentalis across key-person, legal, regulatory, security, operational or financial-integrity risk in three weeks of coverage and 30 days of SEC filings.
Ranges are one standard deviation of volatility around the latest close — about 1 week in 3 moves further. Not a forecast or investment advice.
What it means
- What to watch: Drugmakers live and die by pipelines — what is in late-stage trials matters more than this quarter's sales.
- How the stocks are trading: $ZNTL -7.50%, $SF -2.16%, $HR -0.31% in the latest session.
- Timing: It was published after the close, so the day's move was settled before the story existed. The next session is the first that could react.
Where the stock stands
Zentalis Pharmaceuticals ($ZNTL) dropped 7.50% to $1.48 in the latest session. Over the past month it is down 35.2%. It now sits 79% under the 52-week high of $6.95 and 16% above the year's low of $1.28, close to the bottom of its range. It has been a volatile year: the high was 5.4 times the low, so moves this size are not unusual for it. Stifel Financial ($SF) declined 2.16% to $71.02 in the latest session. Over the past month it is up 7.5%. It now sits 21% under the 52-week high of $89.83 and 8.6% above the year's low of $65.40. Its range over the year spans 37%, which is moderate.
What the filings say
In its latest report (10-Q, filed Nov 9, 2026), $ZNTL lost $28.8M over the quarter to Sep 30, 2026. Operations used $102.9M of cash over the nine months to Sep 30, 2026 — about $11.5M a month — against $24.0M in cash on Sep 30, 2026. At that pace the cash covers about 2 months, which is why financing, asset sales or restructuring tend to come up for companies in this position. Total liabilities were $65.3M against $24.0M of cash on Sep 30, 2026. The company filed an 8-K — the form for material events — on Nov 9, 2 days before this story; it is $ZNTL's own account and the first thing to read. Figures are as filed with the SEC; the $ZNTL page has the full statements.
How much coverage it is getting
Wook has filed 20 stories on these companies in the last 30 days, 6 of them this week. Its 30-day average is about 5 a week, so this week is a little busier than usual. Going by their wording, 25% read bullish, 75% neutral and 0% bearish. This one reads neutral too, in line with most of them. Investing.com wrote 11 of the 20 (55%), so the count reflects one outlet's output more than broad attention.
The bigger picture
In healthcare, the calendar is the catalyst — trial readouts, FDA decisions and pricing rules. One result can move a single drugmaker sharply; a policy change moves the whole aisle. Wook's supply-chain scanner shows no unusual stress in Health Care today.
What to watch next
For the company's side of it, read its latest SEC filings on the $ZNTL page. A US company has to report material news on an 8-K, usually within four business days; foreign issuers use a 6-K. Most of the recent coverage comes from one outlet, so check whether another newsroom has confirmed the story or is only repeating it. Wook AI, at the top of the page, can work out how far $ZNTL is from its high or compare this week's coverage with earlier weeks.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Investing.com published this on November 11, 2026. $ZNTL has moved -20.46% ($1.86 to $1.48), $SF has moved -2.74% ($73.02 to $71.02) and $HR has moved +0.00% ($19.26 to $19.26). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.
